4 / 18
Page 21
Notes:
allied
academies
Ann Clin Trials Vaccines Res. 2017 | Volume 1 Issue 2
Global Vaccines & Vaccination Summit & B2B
November 01-02, 2017 | Toronto, Canada
Development of a
Bovine papillomavirus
VLP vaccine in bacterial host
Diego Grando Módolo
Butantan Institute, Brazil
B
ovine papillomatosis (BP) is an infectious disease, presenting
multiple benign epithelial proliferative lesions. BP causes
economic losses, since affected animals usually show delayed
development, weight loss, reduction of milk flow and leather
quality. There are not yet commercial vaccines against BPV
available up to date. Here, we developed an integrated study
about the L1 capsid protein of BPV-1, obtained from bacterial
expression system, concerning its purification, biosafety,
thermo-stability and immunogenicity. The recombinant
protein was expressed in bacteria and purified by Affinity and
Ion Exchange chromatography. Circular dichroic (CD) spectra
analysis indicated the correct folding of the recombinant L1
protein, suggesting a predominantly β-sheet structure. The
thermostability of the recombinant L1 was accessed through
the CD signal. Provided data revealed a TM value of 55.7
o
C.
The biosafety of the recombinant L1 protein was evaluated by
the cytokinesis-blocked micronucleus test. This test detected a
high frequency of micro nucleated cells in the positive control,
which was not verified in both the negative control and in the
cells treated with the L1 recombinant protein. Complementally,
comet assay indicated similar results. A heterogenic complex of
structures was observed with Transmission ElectronMicroscopy,
with a consistent conformation of both incomplete and complete
VLPs, with approximately 45 and 55 nm, respectively. Structural
capsomeres were also found nearby the virus-like particles. For
prophylactic test, we inoculated by intradermal injection young
calves. After 30 days of the booster dose, antibody levels in
control group did not increase. On the other hand, the group
that received two vaccine doses showed a significant high
production of specific antibodies against recombinant L1 of BPV-
1. Our strategy can be useful to evaluate the efficacy and the
safety of different recombinant vaccine candidates. Moreover,
described recombinant VLPs has proved to be a viable approach
for designing new vaccines against other PVs species, including
the human papillomavirus.
Speaker Biography
Diego Grando Módolo has a PhD degree in Genetics and Molecular Biology, and many
years of experience in production of recombinant antigens in plants and bacteria.
He has his expertise in expression and characterization of recombinant vaccines,
including the production of papillomavirus virus-like particles. He is working at
Butantan Institute, in the Research and Development of innovative solutions in the
area of animal or human health using his experience in biotechnology to produce
biomolecules of pharmaceutical interest.
e:
diego@lgf.ib.unicamp.br